Form 4: IMAX CEO Exercises, Sells Shares Under 10b5-1 Plan
Insider Transaction Report
IMAX CEO Richard L. Gelfond exercised stock options and immediately sold the resulting common shares as part of a pre-arranged 10b5-1 trading plan.
Summary
- Richard L. Gelfond, CEO and Director of IMAX Corp., exercised 121,220 stock options at a price of $31.40 per share on March 10, 2026.
- Concurrently, Mr. Gelfond sold 121,220 common shares at an average price of $40.0993 per share on March 10, 2026.
- These transactions were conducted under a Rule 10b5-1 trading plan dated December 9, 2026.
- Following these transactions, Mr. Gelfond's direct beneficial ownership of common shares remains at 765,002.
- His aggregate remaining outstanding options are 1,697,475, restricted share units are 231,562, and common shares are 765,002.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it's an insider sale, it's pre-planned and profitable, suggesting routine financial management rather than a loss of confidence.
Positives
- The transactions were executed under a pre-arranged 10b5-1 plan, indicating a planned and transparent sale, not a reaction to new, undisclosed information.
- The sale price of $40.0993 per share is higher than the exercise price of $31.40, indicating a profitable transaction for the CEO.
Negatives
- An insider sale, even under a 10b5-1 plan, can sometimes be perceived negatively by the market, suggesting a lack of further upside potential from the insider's perspective.
Industry Context
StockSavvy.ai notes that insider transactions, particularly those executed under 10b5-1 plans, are a routine part of executive compensation and personal financial management across all industries. While the sale itself is not inherently negative, the market often scrutinizes such sales for any underlying signals about management's confidence in future company performance, especially when the volume is significant relative to total holdings.
Stakeholder Impact
- Shareholders: May interpret the sale as a routine liquidity event or, less commonly, as a signal of limited upside, though the 10b5-1 plan mitigates negative interpretations.
- Employees: No direct impact.
- Customers/Suppliers/Creditors: No direct impact.
Key Dates
| Date | Description |
|---|---|
| 2016-06-07 | First installment of stock options became exercisable (162,095 shares). |
| 2016-09-01 | Second installment of stock options became exercisable (162,095 shares). |
| 2016-12-31 | Third installment of stock options became exercisable (162,094 shares). |
| 2026-03-10 | Date of stock option exercise and subsequent sale of common shares. |
| 2026-03-12 | Date the Form 4 was signed by Richard L. Gelfond. |
| 2026-06-07 | Expiration date of the exercised stock options. |
| 2026-12-09 | Date the 10b5-1 trading plan was established. |
Recommendation
holdThe insider transaction is a routine exercise and sale under a pre-arranged 10b5-1 plan, indicating a planned liquidity event rather than a reaction to new information. While profitable for the CEO, it does not provide new fundamental insights into IMAX's operational performance or future prospects that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting further operational updates.
Keywords
IMAX, Richard Gelfond, Form 4, Insider Trading, Stock Options, Share Sale, 10b5-1 Plan, CEO, Director, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.